Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Accounts Payables: 2010-2025

Historic Accounts Payables for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to $6.1 million.

  • Sunshine Biopharma's Accounts Payables rose 47.63% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 47.63%. This contributed to the annual value of $5.5 million for FY2024, which is 114.39% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Accounts Payables of $6.1 million as of Q3 2025, which was up 27.93% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Accounts Payables registered a high of $6.1 million during Q3 2025, and its lowest value of $42,942 during Q4 2021.
  • In the last 3 years, Sunshine Biopharma's Accounts Payables had a median value of $4.2 million in 2024 and averaged $4.0 million.
  • Data for Sunshine Biopharma's Accounts Payables shows a peak YoY increase of 6,426.94% (in 2022) and a maximum YoY decrease of 35.90% (in 2022) over the last 5 years.
  • Over the past 5 years, Sunshine Biopharma's Accounts Payables (Quarterly) stood at $42,942 in 2021, then surged by 6,426.94% to $2.8 million in 2022, then decreased by 7.75% to $2.6 million in 2023, then soared by 114.39% to $5.5 million in 2024, then spiked by 47.63% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $4.8 million for Q2 2025, and $5.0 million during Q1 2025.